| Original language | English (US) |
|---|---|
| Pages (from-to) | 1378-1381 |
| Number of pages | 4 |
| Journal | Diabetes care |
| Volume | 43 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2020 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
COVID-19 in People with Diabetes : Urgently Needed Lessons from Early Reports. / Riddle, Matthew C.; Buse, John B.; Franks, Paul W. et al.
In: Diabetes care, Vol. 43, No. 7, 01.07.2020, p. 1378-1381.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - COVID-19 in People with Diabetes
T2 - Urgently Needed Lessons from Early Reports
AU - Riddle, Matthew C.
AU - Buse, John B.
AU - Franks, Paul W.
AU - Knowler, William C.
AU - Ratner, Robert E.
AU - Selvin, Elizabeth
AU - Wexler, Deborah J.
AU - Kahn, Steven E.
N1 - Funding Information: Funding. This work was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and the Department of Veterans Affairs. Duality of Interest. M.C.R. reports receiving research grant support through Oregon Health & Science University from AstraZeneca, Eli Lilly, and Novo Nordisk and honoraria for consulting from Adocia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Sanofi, and Theracos. J.B.B. reports contracted consulting fees and travel support for contracted activities paid to the University of North Carolina by Adocia, Astra-Zeneca, Dance Biopharm, Eli Lilly, MannKind, NovaTarg, Novo Nordisk, Senseonics, vTv Therapeutics, and Zafgen; grant support from Nova-Targ, Novo Nordisk, Sanofi, Tolerion, and vTv Therapeutics; consulting fees from Cirius Therapeutics Inc., CSL Behring, Mellitus Health, Neurimmune AG, Pendulum Therapeutics, and Stability Health; stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health; and support from the National Institutes of Health (ULITR002489, P30DK124723). P.W.F. reports research grant support from Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi, and Servier; consulting fees from Eli Lilly, Novo Nordisk, and Zoe Global Ltd.; and stock options in Zoe Global Ltd. R.E.R reports having received honoraria for serving as an advisor to Novo Nordisk, Pendulum Therapeutics, and Virta Health. E.S. reports honoraria from Novo Nordisk and grant support from the National Institutes of Health (J24DK106414). D.J.W. reports serving on data monitoring committees for Novo Nordisk. S.E.K. reports having received honoraria for serving as an advisor to Boehringer Ingelheim, Eli Lilly, Intarcia, Janssen, Merck, Novo Nordisk, and Pfizer and grant support from the U.S. Department of Veterans Affairs (101 BX001060) and the National Institutes of Health (P30 DK017047). No other potential conflicts of interest relevant to this article were reported.
PY - 2020/7/1
Y1 - 2020/7/1
UR - http://www.scopus.com/inward/record.url?scp=85086231824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086231824&partnerID=8YFLogxK
U2 - 10.2337/dci20-0024
DO - 10.2337/dci20-0024
M3 - Review article
C2 - 32409505
AN - SCOPUS:85086231824
SN - 1935-5548
VL - 43
SP - 1378
EP - 1381
JO - Diabetes Care
JF - Diabetes Care
IS - 7
ER -